Molecular Analysis for Personalised Therapy 2015
Oncology Meeting Resources
23 Oct - 24 Oct, Paris, France
This new conference explored the clinical interpretation of molecular tests for metastatic cancers, where the development of new biotechnologies has revolutionised the applications of personalised therapy. This emerging topic was discussed in detail and offered oncologists practical solutions for clinical treatment.
Webcasts from the Molecular Analysis for Personalised Therapy 2015 are now available here. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
|Presenter||Presentation title||Session title|
|Elaine Mardis||Analytical validity of next generation sequencing for clinical use||Introduction to personalised medicine|
|Fabrice Andre||Level of evidence scale for genomic alterations||Introduction to personalised medicine|
|Christos Sotiriou||Genomic drivers in breast cancers||Actionable genomic alterations in frequent cancers|
|Jean Feunteun||Tumour suppressor genes: is the loss of second allele a mandatory event?||Toward rules to identify drivers in individuals|
|Andrew Biankin||Finding the trial for the patient: the new paradigm of therapeutic development for precision oncology||Beyond driver identification: what can we expect from molecular analyses?|
|Leanne de Koning||Protein-based assay: how to position them in personalised medicine trials?||Beyond driver identification: what can we expect from molecular analyses?|
|Jordi Rodón||What have we learnt from personalised medicine trials? Molecular screening programmes||What have we learnt from personalised medicine trials?|
|Jean Charles Soria||Personalised medicine trials: Gustave Roussy experience||What have we learnt from personalised medicine trials?|
|Gary Middleton||Driver Identification in Advanced Non-Small Cell Lung Cancer||What have we learnt from personalised medicine trials?|